Loading...
Powered By
21 items
2025-07-10
Nippon Shinyaku Co., Ltd., Q1 2026 Earnings Call, Aug 07, 2025
2025-06-10
Nippon Shinyaku Co., Ltd. announced that they will report Q1, 2026 results on Aug 07, 2025
2025-05-13
Nippon Shinyaku Co., Ltd. provided earnings guidance for the fiscal first half ending September 30, 2026 and full year ending March 31, 2026. For the first half, the company expects revenue to be JPY 81,500 million, operating profit to be JPY 16,000 million, net income attributable to owners of the parent to be JPY 12,800 million or basic earnings per share to be JPY 189.97. For the year, the company expects revenue to be JPY 173,000 million, operating profit to be JPY 30,000 million, net income attributable to owners of the parent to be JPY 24,000 million or basic earnings per share to be JPY 356.20.
2025-05-13
Nippon Shinyaku Co., Ltd. announced dividend of JPY 62.00 per share for the fiscal full year ended March 31, 2025 against JPY 62.00 per share a year ago. Scheduled date of commencing dividend payments is June 30, 2025. The company provided dividend guidance for the fiscal first half of 2026 and full year ending March 31, 2026. For the first half, the company expects to pay dividend of JPY 62.00 per share against JPY 62.00 per share a year ago. For the year, the company expects to pay dividend of JPY 62.00 per share against JPY 62.00 per share a year ago.
2025-05-08
Nippon Shinyaku Co., Ltd., Annual General Meeting, Jun 27, 2025.
2025-05-08
Nippon Shinyaku Co., Ltd. expected to report Q1 2026 results on August 8, 2025. This event was calculated by S&P Global (Created on May 8, 2025).
2025-04-15
Nippon Shinyaku Co., Ltd., Q4 2025 Earnings Call, May 08, 2025
2025-03-04
REGENXBIO Inc. announced the closing of its previously announced strategic partnership with Nippon Shinyaku. Under the terms of the agreement, REGENXBIO and Nippon Shinyaku will develop and commercialize RGX-121 (clemidsogene lanparvovec) for Mucopolysaccharidosis II (MPS II), also known as Hunter syndrome and RGX-111 for MucopolysaccharIDosis I (MPS I), also known as Hurler syndrome in the United States and Asia. RGX-111 has received Orphan Drug Product, Rare Pediatric Disease and Fast Track designations from the U.S. Food and Drug Administration.
2025-02-28
Nippon Shinyaku Co., Ltd. announced that they will report fiscal year 2025 results at 3:00 PM, Tokyo Standard Time on May 08, 2025
2025-02-13
Small meeting for sell-side analysts
2025-02-01
Nippon Shinyaku Co., Ltd. expected to report Fiscal Year 2025 results on May 9, 2025. This event was calculated by S&P Global (Created on February 1, 2025).
2025-01-17
REGENXBIO Inc. and Nippon Shinyaku Co., Ltd. announced a strategic partnership for the development and commercialization of RGX-121 for the treatment of Mucopolysaccharidosis II (MPS II), also known as Hunter syndrome, and RGX-111 for Mucopolysaccharidos I (MPS I), also known as Hurler syndrome. Under the terms of the agreement, REGENXBIO will receive $110 million at closing and up to an additional $700 million if certain milestones are achieved, consisting of $40 million in potential development and regulatory milestones and $660 million in potential sales milestones. REGENXBIO will also receive meaningful double-digit royalties on net sales in the U.S. and Asia (collectively, the Licensed Territory). This partnership with Nippon Shinyaku is exciting in that it maximizes collective strengths and enables access of two potentially transformational medicines to key markets, said Curran M. Simpson, President and Chief Executive Officer, REGENXBIO. REGENXBIO retains all rights to, and 100% of any proceeds related to the sale of, the Priority Review Voucher (PRV) for RGX-121 received upon potential approval. REGENXBIO is lead the manufacturing of both products for clinical and commercial supply in the Licensed Territory. The transaction is expected to close by the end of the first quarter of 2025, subject to the customary conditions, including applicable regulatory approvals. RGX-121 is a potential one-time AAV therapeutic for the treatment of boys with MPS II. RGX-121 expressed protein is structurally identical to normal I2S.
2025-01-06
R&D Meeting 2024
2025-01-06
Nippon Shinyaku Co., Ltd., Q3 2025 Earnings Call, Feb 07, 2025
2024-12-07
Nippon Shinyaku Co., Ltd. announced that they will report Q3, 2025 results on Feb 07, 2025
2024-11-14
Nippon Shinyaku Co., Ltd., ¥ 62.0, Cash Dividend, Mar-28-2025
2024-11-13
Nippon Shinyaku Co., Ltd. expected to report Q3 2025 results on February 7, 2025. This event was calculated by S&P Global (Created on November 13, 2024).
2024-10-22
Capricor Therapeutics, Inc. has filed a Shelf Registration in the amount of $52.779842 million. Security Name: COMMON STOCK Securities Offered: 2,798,507
2024-10-21
Nippon Shinyaku Co., Ltd., Q2 2025 Earnings Call, Nov 15, 2024
2024-09-27
Nippon Shinyaku Co., Ltd. announced that they will report Q2, 2025 results on Nov 13, 2024
2024-09-17
Capricor Therapeutics, Inc. announced that it has entered into a subscription agreement to issue $5.36 per share for the gross proceeds of $14,999,998 on September 16, 2024. The transaction included participation from new investor, Nippon Shinyaku Co., Ltd. The Subscription Agreement also includes lock-up provisions restricting Nippon Shinyaku from selling or otherwise disposing of shares of Common Stock until the six month anniversary of the Closing Date.
2025Q2 | 2025Q1 | 2024Q4 | 2024Q3 | 2024Q2 | 2024Q1 | 2023Q4 | 2023Q3 | |
|---|---|---|---|---|---|---|---|---|
Total Revenues | 160,647 | 160,232 | 156,847 | 154,273 | 150,374 | 148,255 | 146,984 | 146,353 |
Pretax Income Excl.Unusual Items | 36,270 | 37,178 | 37,178 | 31,765 | 34,684 | 34,713 | 33,808 | 33,007 |
Total Assets | 289,625 | 283,637 | 284,459 | 268,542 | 265,828 | 263,404 | 247,830 | 249,499 |
Total Liabilities | 37,792 | 36,297 | 36,677 | 33,291 | 38,366 | 42,870 | 32,514 | 37,725 |
Cash & Cash Equivalents | 58,277 | 55,241 | 55,421 | 56,387 | 54,472 | 58,094 | 57,323 | 62,855 |
Total Common Equity | 251,521 | 247,028 | 247,469 | 234,936 | 227,147 | 220,224 | 215,007 | 211,466 |
Book Value Per Share (BVPS) | 3,732.95 | 3,666.27 | 3,672.81 | 3,486.79 | 3,372.5 | 3,269.71 | 3,192.25 | 3,139.68 |
Net Change in Cash | 3,805 | -2,852 | -1,901 | -6,466 | -779 | -1,953 | 2,405 | -594 |
Capital Expenditure | -3,271 | -3,352 | -5,280 | -4,347 | -4,354 | -5,058 | -3,941 | -4,792 |
On August 07, 2025, Nippon Shinyaku shared its financial results for the second quarter of 2025, having revenues of 39.55B yen and net income of 8.26B yen, indicating a growth of 1.1% in revenue, along with a decrease of approximately 19.6% in EPS compared with the same quarter last year. A positive note is that for the 12th consecutive quarter, the company's revenue line has increased compared to last year's corresponding quarter, which demonstrates the company's stability and its ability to grow in the future.
In addition, the EBITDA margin moderate decline from 32.1% in the corresponding quarter last year to 29.5%. Another notable figure in the negative aspect is the free cash flow for the quarter, which was 5.92B yen, decreased by -0.12B from the previous year's corresponding period. and it trades at 7.1x times current year's earnings, which is lower than the sector average (P/E 9.6x).